Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.

After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.

BGB-16673 and BGB-43395 will soon both be in phase 3 trials, BeiGene reveals.

Meanwhile, Tango tries again in PRMT5.

AstraZeneca bags three of the month’s four oncology approvals.

But with Brukinsa and degraders looming, will fixed dosing make the difference?

Crossover scuppers Jaypirca's survival benefit, but full approval seems likely.

First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.

NX-5948 and BGB-16673 yield data in more CLL patients, but Nurix investors seem unimpressed.